The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Focal Ultrasound Ablation Demonstrates Utility as Primary Therapy in Prostate Cancer
September 15th 2020Hemigland high-intensity focused ultrasound ablation of the prostate was found to be a safe and effective primary treatment for men with localized prostate cancer, leading to continence preservation and suitable short-term disease control.
Emerging Evidence Supports the Use of Narsoplimab in HSCT-TMA
August 31st 2020Rafael F. Duarte, MD, PhD, FRCP, presents 2 real-world clinical cases in which the investigational monoclonal antibody narsoplimab demonstrated clinical benefit in patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Tipifarnib Exhibits Enriched Activity in HRAS-Mutant Head and Neck Cancer
August 20th 2020Tipifarnib demonstrated encouraging antitumor activity in patients with recurrent and metastatic head and neck cancer with high HRAS-mutant variant allele frequency, surpassing historical competitors in the second- or later-line settings.
Next-Generation Sequencing Shows Marked Potential for Diagnostic Improvements in MPNs
August 13th 2020Patients with a suspected or diagnosed myeloproliferative neoplasm should undergo targeted next-generation sequencing versus sequential or allele specific testing to reduce the risk of identifying a false driver mutation or an excluded diagnosis of MPN.
Novel Triplet Emerges as a Promising Option in BRAF-Mutant Melanoma
August 13th 2020Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the safety profile of the combination of spartalizumab, dabrafenib, and trametinib, the clinical implications of the biomarker data observed from this trial, and other emerging combinations on the horizon.
FDA Grants Adjuvant Osimertinib Breakthrough Status in Early-Stage EGFR+ NSCLC
July 30th 2020The FDA has granted a breakthrough therapy designation to osimertinib for the adjuvant treatment of patients with stage IB, II, and IIIA EGFR-mutated non–small cell lung cancer following complete resection with curative intent.
Early Biomarker Data Provide Framework for Precision Medicine-Based Trials in Prostate Cancer
July 2nd 2020Liquid biopsy with circulating tumor DNA could help alleviate some of the challenges of tissue biopsy in prostate cancer, and in doing so, lead to a better precision medicine model in the field.
Frontline 4-Drug Atezolizumab Regimen Shows Tolerability and Minimal Treatment Burden in NSCLC
June 11th 2020The 4-drug ABCP regimen improved survival while maintaining good health-related quality of life in patients with nonsquamous non–small cell lung cancer, according to patient-reported outcomes from the phase 3 IMpower150 trial.
Pembrolizumab Combo Falls Short in Phase 3 Frontline Urothelial Carcinoma Trial
June 10th 2020Adding pembrolizumab to chemotherapy did not lead to a statistically significant improvement in overall survival or progression-free survival in patients with advanced or metastatic urothelial carcinoma, according to findings from the phase 3 KEYNOTE-361 trial.